Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

RAPT RAPT Therapeutics Inc

4,55

0,55 (13,75%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:34:54

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more RAPT Therapeutics Charts.

RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more RAPT Therapeutics Charts.

News RAPT Therapeutics Inc

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 9 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

RAPT Therapeutics Reports First Quarter 2024 Financial Results
Donnerstag 9 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Dienstag 9 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Donnerstag 7 März 2024 (2 Monate vor) • GlobeNewswire Inc.

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Dienstag 5 März 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Donnerstag 22 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 20 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
Dienstag 20 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere RAPT Therapeutics Inc News-Artikel

BNP Paribas (QX)

Deutsche Lufthansa

JP Morgan Chase

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen